Efficacy of acarbose in different geographical regions of the world: Analysis of a real-life database

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 2, 2015, Pages 155-167

  Weng, Jianping ^a,b   Soegondo, Sidartawan ^c   Schnell, Oliver ^d   Sheu, Wayne H H ^e   Grzeszczak, Wladyslaw ^f   Watada, Hirotaka ^g   Yamamoto, Noriyuki ^h   Kalra, Sanjay ⁱ  

^a Environmental Pollution Control and Remediation Technology   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF INDONESIA   (Indonesia)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h Bayer Healthcare Co   (China)

ⁱ Bharti Research Institute of Diabetes and Endocrinology ^*  (India)

Author keywords

Acarbose; Asian; Diabetes mellitus; Ethnicity; European Caucasian; Non interventional study

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CAUCASIAN; COMORBIDITY; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; EAST ASIAN; ETHNICITY; EUROPEAN; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SOUTH ASIAN; SOUTHEAST ASIAN; UNDERWEIGHT; ANALYSIS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG RESISTANCE; ETHNOLOGY; FACTUAL DATABASE; HYPERGLYCEMIA; MULTIVARIATE ANALYSIS; POSTMARKETING SURVEILLANCE;

ACARBOSE; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS; DRUG RESISTANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GLYCOSIDE HYDROLASE INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MULTIVARIATE ANALYSIS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84922683718     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2576     Document Type: Article

References (67)

1. International Diabetes Federation. Diabetes Atlas (fifth edn). IDF: Brussels, 2011.
2. International Diabetes Federation. Diabetes Atlas (sixth edn). IDF: Brussels, 2013.
3. World Health Organization. Diabetes. Fact sheet no 312. WHO: Geneva, 2013.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013; 19: 327-336.
6. International Diabetes Federation. Global Guideline for Type 2 Diabetes. IDF: Brussels, 2012.
7. Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors' expert forum. Diabetes Care 2013; 36: 1779-1788.
8. Derosa G, Maffioli P. Alpha-glucosidase inhibitors and their use in clinical practice. Arch Med Sci 2012; 8: 899-906.
9. Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diab Metab Syndr Obes 2012; 5: 357-367.
10. Bischoff H. The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clin Invest Med 1995; 18: 303-311.
11. Standl E, Schnell O. Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012; 9: 163-169.
12. Bayer. Acarbose Summary of Product Characteristics. Bayer: Newbury, 2012.
13. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007; 30: 263-269.
14. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
15. Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev 2011; 27: 79-84.
16. International Diabetes Federation. 2011 Guideline for Management of Postmeal Glucose in Diabetes. IDF: Brussels, 2011.
17. Sheu WH, Rosman A, Mithal A, et al. Addressing the burden of type 2 diabetes and cardiovascular disease through the management of postprandial hyperglycaemia: an Asian-pacific perspective and expert recommendations. Diabetes Res Clin Pract 2011; 92: 312-321.
18. Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-737.
19. Hotta N, Kakuta H, Sano T, et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabet Med 1993; 10: 134-138.
20. Chan JC, Chan KW, Ho LL, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Diabetes Care 1998; 21: 1058-1061.
21. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-935.
22. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (bay g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-451.
23. Braun D, Schonherr U, Mitzkat H-J. Efficacy of acarbose monotherapy in patients with type 2 diabetes: a double-blind study conducted in general practice. Endocrinol Metab 1996; 3: 275-280.
24. Hasche H, Mertes G, Bruns C, et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 1999; 12: 277-285.
25. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998; 21: 2050-2055.
26. Halimi S, Le Berre MA, Grange V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49-56.
27. Phillips P, Karrasch J, Scott R, et al. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-273.
28. Sumual AR, Pandelaki K, Rotty LAW. Acarbose/metformin combination versus metformin alone in Indonesian patients with type 2 diabetes. J ASEAN Fed Endocr Soc 2003; 21: 24-31.
29. Costa B, Piñol C. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes Res Clin Pract 1997; 38: 33-40.
30. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999; 16: 755-761.
31. Lin BJ, Wu HP, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003; 17: 179-185.
32. Bachmann W, Petzinna D, Raptis SA, et al. Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy. Clin Drug Investig 2003; 23: 679-686.
33. Segal P, Eliahou H, Petzinna D, et al. Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Clin Drug Investig 2005; 25: 589-595.
34. Lam KS, Tiu SC, Tsang MW, et al. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. Diabetes Care 1998; 21: 1154-1158.
35. Wang JS, Huang CN, Hung YJ, et al. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Res Clin Pract 2013; 102: 16-24.
36. Wang JS, Lin SD, Lee WJ, et al. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2011; 33: 1932-1942.
37. Pan CY, Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in china. Clin Drug Investig 2007; 27: 397-405.
38. van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163.
39. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 2: CD003639.
40. Zhu Q, Tong Y, Wu T, et al. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an eastern or western diet: a systematic meta-analysis. Clin Ther 2013; 35: 880-899.
41. Cai X, Han X, Luo Y, Ji L. Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian. PLoS One 2013; 8: e79421.
42. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan diabetes society to national glycohemoglobin standardization program values. J Diab Investig 2012; 3: 39-40.
43. Hara T, Nakamura J, Koh N, et al. An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM. Diabetes Care 1996; 19: 642-647.
44. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. J Am Med Assoc 2009; 301: 2129-2140.
45. Hu EA, Pan A, Malik V, Sun Q. White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review. BMJ 2012; 344: e1454.
46. Burden ML, Samanta A, Spalding D, Burden AC. A comparison of the glycaemic and insulinaemic effects of an Asian and a European meal. Pract Diab Int 1994; 11: 208-211.
47. Misra A, Khurana L, Isharwal S, Bhardwaj S. South Asian diets and insulin resistance. Br J Nutr 2009; 101: 465-473.
48. Henry CJ, Lightowler HJ, Newens K, et al. Glycaemic index of common foods tested in the UK and India. Br J Nutr 2008; 99: 840-845.
49. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66(Suppl 1): S37-43.
50. Jayaram S, Hariharan RS, Madhavan R, et al. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes. J Assoc Physicians India 2010; 58: 679-682, 687.
51. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the stop-NIDDM trial. J Am Med Assoc 2003; 290: 486-494.
52. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16.
53. May C. Wirksamkeit und verträglichkeit von einschleichend dosierter acarbose bei patienten mit nicht-insulinpflichtigem diabetes mellitus (typ-2 diabetes) unter sulfonylharnstoffen. Diabetol Stoffwechsel 1995; 4: 3-8 (in German).
54. Patnaik R, Chauhan P. India at the cross-roads of human evolution. J Biosci 2009; 34: 729.
55. Dickinson S, Colagiuri S, Faramus E, et al. Postprandial hyperglycemia and insulin sensitivity differ among lean young adults of different ethnicities. J Nutr 2002; 132: 2574-2579.
56. Hanefeld M, Koehler C, Schaper F, et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999; 144: 229-235.
57. Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 1345-1350.
58. Kalra S, Plata-Que T, Kumar D, et al. Initiation with once-daily biasp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs. Diabetes Res Clin Pract 2010; 88: 282-288.
59. Davidson JA, Lacaya LB, Jiang H, et al. Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. Endocr Pract 2010; 16: 818-828.
60. Kalra S, Balhara YPS, Sahay BK, et al. Why is premixed insulin the preferred insulin? Novel answers to a decade-old question. J Assoc Physicians India 2013; 61: 9-11.
61. Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care 2013; 36: 1789-1796.
62. John M, Kalra S, Unnikrishnan AG, et al. Recommendations for insulin initiation based on ethnicity. Med Hypotheses 2011; 77: 460-461.
63. Spengler M, Schmitz H, Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus: a postmarketing surveillance study. Clin Drug Investig 2005; 25: 651-659.
64. Li C, Hung YJ, Qamruddin K, et al. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 92: 57-64.
65. Zhang W, Kim DJ, Philip E, et al. A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the GlucoVIP study. Clin Drug Invest 2013; 33: 263-274.
66. Hung YJ, Kuo SW, Wang CH, et al. Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clin Drug Investig 2006; 26: 559-565.
67. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. prospective diabetes study 44). Diabetes Care 1999; 22: 960-964.